[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562176":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":38,"responsibleParty":57,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":11,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":41,"whyStopped":11,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Manitoba","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic Acid","EXPERIMENTAL",null,[13],"Drug: Tranexamic acid",{"label":15,"type":16,"description":11,"interventionNames":17},"Matching Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Tranexamic acid","Tranexamic acid 1000mg orally two or three times daily",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","Placebo orally two or three times daily",[15],[30,35],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Brett Houston, MD, PhD","CONTACT","204-787-8552","bhouston@cancercare.mb.ca",{"name":36,"role":32,"phone":33,"phoneExt":11,"email":37},"Nora Choi, MSc","nchoi@hsc.mb.ca",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"CancerCare Manitoba","RECRUITING","Winnipeg","Manitoba","R3E 0V9","Canada","CA",{"type":48,"coordinates":49},"Point",[50,51],-97.14704,49.8844,{"lat":51,"lon":50},[54],{"name":55,"role":32,"phone":56,"phoneExt":11,"email":34},"Brett Houston, MD","204-787-1103",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Brett Houston","Principal Investigator","100562176","phase-2-evaluation-of-tranexamic-acid-in-myelodysplastic-syndromes-and-acute-myeloid-leukemia-100562176",false,"NCT06599762","Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia","Evaluation of Tranexamic Acid Among Outpatients With Myelodysplastic Syndromes and Acute Myeloid Leukemia: a Multicenter Pilot Trial","MYELO-CAN:TXA","Inclusion Criteria:\n\nMaster platform inclusion criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of myelodysplastic syndromes, myelodysplastic\u002Fmyeloproliferative neoplasm or acute myeloid leukemia\n\nMYELO-CAN TXA inclusion criteria:\n\n1. Receipt of less-intensive chemotherapy (includes both frontline and relapsed\u002Frefractory setting)\n2. Severe thrombocytopenia (platelets ≤ 30x10\\^9\u002FL or platelets ≤ 50x10\\^9\u002FL prior to chemotherapy initiation)\n\nExclusion Criteria:\n\nMaster platform exclusion criteria:\n\n1. Participant is deemed unlikely to survive \\>30 days (as determined by clinical team)\n2. Participant unable to provide informed consent\n\nMYELO-CAN TXA exclusion criteria:\n\n1. Known allergy to tranexamic acid\n2. Active thromboembolic disease\n3. Active ischemic heart disease\n4. Gross hematuria\n5. Stage V chronic kidney disease\n6. Clinically suspected disseminated intravascular coagulation (DIC)\n7. Pregnancy and\u002For breastfeeding","ALL","18 Years",{"count":72,"type":73},75,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life changing blood cancers. Patients with MDS and AML commonly experience complications related to bleeding, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of tranexamic acid (TXA; a medication that prevents clots from dissolving) to prevent bleeding. In this study, 50% of patients will be randomized (like the flip of a coin) to receive TXA; the other 50% of patients will receive placebo. The investigators will monitor both groups of patients to see if the medication improves the risk and\u002For severity of bleeding. If tranexamic acid were to safely reduced the frequency of bleeding, this would broadly influence how doctors provide care for patients with MDS and AML around the world.",[79,80,81],"Myelodysplastic Syndromes","Acute Myeloid Leukemia","Myelodysplastic\u002FMyeloproliferative Neoplasm",[9,83,84,80,85,86,87],"Randomized Controlled Trial","Myelodysplastic Syndrome","Thrombocytopenia","myelodysplastic\u002Fmyeloproliferative neoplasm","myeloproliferative neoplasm","2026-04-20",{"date":90,"type":91},"2026-04-22","ACTUAL",{"date":93,"type":91},"2025-09-10",{"date":95,"type":73},"2027-04-01",{"name":5,"class":6},1]